Archive for February 2023
Immunexpress Begins US Commercialization of Near-Patient Sepsis Diagnostic Test
New Publication Validates SeptiCyte® RAPID as a Triaging Tool for COVID-19 Patients
SeptiCyte RAPID accurately assessed COVID-19 severity Elevated SeptiScore upon hospital intake was predictive of ICU admission SeptiCyte RAPID performed better than single-biomarker assays that are routinely used to assess COVID-19 severity SEATTLE and BRISBANE, Australia, Feb. 2, 2023 /PRNewswire/ — Immunexpress, Pty Ltd., a molecular diagnostic company focused on improving outcomes for suspected sepsis patients,…
Read More